Cargando…

Prospective validation of a novel dosing scheme for intravenous busulfan in adult patients undergoing hematopoietic stem cell transplantation

The objective of this study was to externally validate a new dosing scheme for busulfan. Thirty-seven adult patients who received busulfan as conditioning therapy for hematopoietic stem cell transplantation (HCT) participated in this prospective study. Patients were randomized to receive intravenous...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Sang-Heon, Lee, Jung-Hee, Lim, Hyeong-Seok, Lee, Kyoo-Hyung, Kim, Dae-Young, Choe, Sangmin, Bae, Kyun-Seop, Lee, Je-Hwan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Physiological Society and The Korean Society of Pharmacology 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4860366/ https://www.ncbi.nlm.nih.gov/pubmed/27162478 http://dx.doi.org/10.4196/kjpp.2016.20.3.245

Ejemplares similares

A Simple Dosing Scheme for Intravenous Busulfan Based on Retrospective Population Pharmacokinetic Analysis in Korean Patients
por: Choe, Sangmin, et al.
Publicado: (2012)

Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia
por: Lee, Seung-Shin, et al.
Publicado: (2020)

Comparison of levetiracetam with phenytoin for the prevention of intravenous busulfan-induced seizures in hematopoietic cell transplantation recipients
por: Akiyama, Kana, et al.
Publicado: (2018)

Pharmacokinetic comparison of sustained- and immediate-release formulations of cilostazol after multiple oral doses in fed healthy male Korean volunteers
por: Kim, Yo Han, et al.
Publicado: (2015)

Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation
por: Kamijo, Kimimori, et al.
Publicado: (2023)

Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms
por: Lim, Sung-Nam, et al.
Publicado: (2013)

Population pharmacokinetics of oral high-dose busulfan in adult patients undergoing hematopoietic stem cell transplantation
por: Hadjibabaie, M., et al.
Publicado: (2011)

Population Pharmacokinetics of Busulfan and Its Metabolite Sulfolane in Patients with Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation
por: Dadkhah, Adrin, et al.
Publicado: (2022)

Impact of GSTA1 Polymorphisms on Busulfan Oral Clearance in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation
por: Michaud, Veronique, et al.
Publicado: (2019)

Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
por: Seydoux, Claire, et al.
Publicado: (2020)

Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
por: Ji, Young Sok, et al.
Publicado: (2016)

Association of CTH variant with sinusoidal obstruction syndrome in children receiving intravenous busulfan and cyclophosphamide before hematopoietic stem cell transplantation
por: Huezo-Diaz Curtis, P, et al.
Publicado: (2018)

Precision dosing of intravenous busulfan in pediatric hematopoietic stem cell transplantation: Results from a multicenter population pharmacokinetic study
por: Ben Hassine, Khalil, et al.
Publicado: (2021)

Antitumor Activity and Neutrophil‐selective Hematopoietic Toxicity of Busulfan Analogs in Mice
por: Kato, Taketoshi, et al.
Publicado: (1988)

Phenytoin as seizure prophylaxis in hematopoietic stem cell transplantation with busulfan conditioning
por: Germeraad, R. S., et al.
Publicado: (2022)

Therapeutic Drug Monitoring of Busulfan in Patients Undergoing Hematopoietic Cell Transplantation: A Pilot Single-Center Study in Taiwan
por: Chen, Rong-Long, et al.
Publicado: (2021)

GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study
por: Ansari, Marc, et al.
Publicado: (2017)

Hemorrhagic cystitis following allogeneic hematopoietic cell transplantation.
por: Lee, Gyeong-Won, et al.
Publicado: (2003)

Quantification of Human Plasma-Busulfan Concentration by Liquid Chromatography-Tandem Mass Spectrometry
por: Moon, Soo Young, et al.
Publicado: (2014)

Saliva as a noninvasive sampling matrix for therapeutic drug monitoring of intravenous busulfan in Chinese patients undergoing hematopoietic stem cell transplantation: A prospective population pharmacokinetic and simulation study
por: Xu, Baohua, et al.
Publicado: (2023)

Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemia
por: Pidala, Joseph, et al.
Publicado: (2010)

Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects
por: Cho, Yong-Soon, et al.
Publicado: (2018)

Allogeneic hematopoietic cell transplantation for acute leukemia in first relapse or second remission
por: Lee, Je-Hwan, et al.
Publicado: (2010)

Successful hematopoietic stem cell transplantation with reduced dose of busulfan for Omenn syndrome
por: Matsukawa, Yukihiro, et al.
Publicado: (2022)

Effect of pharmacokinetics and pharmacogenomics in adults with allogeneic hematopoietic cell transplantation conditioned with Busulfan
por: Seydoux, Claire, et al.
Publicado: (2023)

Compensatory proliferation of endogenous chicken primordial germ cells after elimination by busulfan treatment
por: Lee, Hyung Chul, et al.
Publicado: (2013)

Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study
por: Liu, Hui, et al.
Publicado: (2013)

Treatment of BK virus-associated hemorrhagic cystitis with low-dose intravenous cidofovir in patients undergoing allogeneic hematopoietic cell transplantation
por: Lee, Seung-Shin, et al.
Publicado: (2015)

Forensic science meets clinical pharmacology: pharmacokinetic model based estimation of alcohol concentration of a defendant as requested by a local prosecutor's office
por: Lim, Hyeong-Seok, et al.
Publicado: (2017)

Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation
por: Seydoux, Claire, et al.
Publicado: (2022)

What is the minimum adequate busulfan dose for patients with sickle cell disease undergoing reduced intensity conditioning with fludarabine, busulfan, and anti‐thymocyte globulin?
por: AlJohani, Naif I., et al.
Publicado: (2021)

A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma
por: Radhakrishnan, Sabarinath V., et al.
Publicado: (2019)

Effects of intravenous multiple busulfan injection on suppression of endogenous spermatogenesis in recipient stallion testes
por: Jung, Heejun, et al.
Publicado: (2021)

Characterization and quantitation of busulfan DNA adducts in the blood of patients receiving busulfan therapy
por: Guidolin, Valeria, et al.
Publicado: (2023)

Combining Mobilizing Agents with Busulfan to Reduce Chemotherapy-Based Conditioning for Hematopoietic Stem Cell Transplantation
por: Garcia-Perez, Laura, et al.
Publicado: (2021)

Dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study
por: Kim, Yo Han, et al.
Publicado: (2015)

Economic and clinical aspects of intravenous versus oral busulfan in adult patients for conditioning prior to HSCT
por: Berger, Karin, et al.
Publicado: (2015)

Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide
por: Lee, Ji Hyun, et al.
Publicado: (2010)

Is there any difference between busulfan-cyclophosphamide and cyclophosphamide-busulfan in patients underwent allogeneic transplantation?
por: Bahçecioğlu, Ömer Faruk, et al.
Publicado: (2021)

Treatment and clinical outcomes of patients relapsing after allogeneic hematopoietic cell transplantation for myelodysplastic syndrome
por: Choi, Eun-Ji, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_m96blni2na7aip6irsta15thut